Nycomed is expanding its presence in Latin America through the acquisition of Laboratorios Farmacol S.A., a Colombia based pharmaceutical company, which has a strong presence in the areas of gastroenterology, respiratory and gynaecology.

Pfizer Japan Inc. ("Pfizer", headquarters: Shibuya-ku, Tokyo) and Takeda Pharmaceutical Company Limited ("Takeda", headquarters: Chuo-ku, Tokyo) announced an agreement to extend the period for co-promotion in Japan for the rheumatoid arthritis (RA) drug Enbrel® (generic name: etanercept).

Total Group turnover for the year declined 1% to £28.4 billion, with pharmaceutical turnover down 2% to £23.4 billion and Consumer Healthcare sales up 5% to £5.0 billion. Excluding pandemic products, Valtrex and Avandia, Group sales were up 4.5% for the year.

Group sales were stable in local currencies at 47.5 billion Swiss francs (-3% in Swiss francs; 1% in US dollars). The good underlying growth of both divisions compensated for the expected decline in Tamiflu sales and the impacts of healthcare reforms and austerity measures.

Sales increased by 19% in Danish kroner and by 13% measured in local currencies, which is slightly higher than the latest guidance of '11-12% growth in local currencies'. All regions contributed to growth measured in local currencies; North America was the main contributor with 62% share of growth measured in local currencies, followed by International Operations and Europe, contributing 24% and 12%, respectively.

Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2010. Since the acquisition of Wyeth was completed on October 15, 2009, fourth-quarter and full-year 2009 results reflect the legacy Wyeth operations from the acquisition date through Pfizer's domestic and international year-ends; results for all periods in 2010 reflect the legacy Wyeth operations.

Pfizer Inc. (NYSE: PFE) announced that its wholly-owned subsidiary, Parker Tennessee Corp., has accepted for purchase all of the shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common stock of King Pharmaceuticals, Inc. (NYSE: KG)